---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-027117"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2022-12-30T23:59:59+00:00"
generated_at: "2026-06-20T21:40:14.966833+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics draws $15M second tranche under $45M loan facility with Avenue Venture

## Summary
- Completed $15M draw on Dec 29, 2022, as second tranche of $30M committed under Aug 8, 2022 Loan Agreement.
- Total facility provides up to $45M in term loans; $15M was funded at closing, $15M now drawn.
- Loan from Avenue Venture Opportunities Fund; terms previously filed and unchanged.

## SEC filing metadata
- accession: 0000950170-22-027117
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2022-12-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017022027117/0000950170-22-027117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017022027117/rani-20221229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-027117
- JSON: https://secwatch.observer/filing/0000950170-22-027117.json
- Plain text: https://secwatch.observer/filing/0000950170-22-027117.txt

## Key facts
- Debt Financings
  Rani Therapeutics Holdings, Inc. incurred term loan of $15 million with Avenue Venture Opportunities Fund, L.P..
  - Instrument: term loan
  - Principal: $15 million
  - Counterparty: Avenue Venture Opportunities Fund, L.P.
  - Event: incurrence
  source text: On December 29, 2022 (the “Borrowing Date”), Rani Therapeutics Holdings, Inc. (“Rani Holdings”) completed a draw down of $15 million under a Loan and Security Agreement and related Supplement dated August 8, 2022 (the “Loan Agreement”), by and among Rani Holdings, Rani Therapeutics, LLC and Rani Management Services, Inc., and Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017022027117/0000950170-22-027117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.